retatrutide dosage trials clinical trial dosing frequency microdosing: guide to split protocols and schedules The Retatrutide Chart: A – Retatrutide Dosing: Early Clinical Trial

Precision matters most at the starting dose because the absolute volumes are small

Barragn JM, Rodrguez RE, Blzquez E: Changes in arterial blood pressure and heart rate induced by glucagon-like peptide-1-(7-36 amide) in rats

Importantly, the current clinical landscape reflects ongoing interest in this concept: while Roche has discontinued development of an NPY2R agonist, Gubra is advancing an NPY2R program in collaboration with Boehringer Ingelheim, suggesting that the hypothesis of pharmacologically optimized Y2 receptor engagement retains translational credibility

Retatrutide extends the same class further as a triple receptor agonist, targeting the GLP-1, GIP, and glucagon receptors together, with the added glucagon activity aimed at boosting energy expenditure alongside appetite suppression

No large-scale study has yet directly followed weight regain for more than one year after discontinuation